98%
921
2 minutes
20
Purpose: To investigate associations between 4-yr change in step cadence and markers of cardiometabolic health in people with a history of prediabetes and to explore whether these associations are modified by demographic factors.
Methods: In this prospective cohort study, adults, with a history of prediabetes, were assessed for markers of cardiometabolic health (body mass index, waist circumference, high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C], triglycerides, and glycated hemoglobin A1c [HbA1c]), and free-living stepping activity (activPAL3™) at baseline, 1 yr, and 4 yr. Brisk steps per day were defined as the number of steps accumulated at ≥100 steps per minute and slow steps per day as those accumulated at <100 steps per minute; the mean peak stepping cadence during the most active 10 minutes of the day was also derived. Generalized estimating equations examined associations between 4-yr change in step cadence and change in cardiometabolic risk factors, with interactions by sex and ethnicity.
Results: Seven hundred ninety-four participants were included (age, 59.8 ± 8.9 yr; 48.7% women; 27.1% ethnic minority; total steps per day, 8445 ± 3364; brisk steps per day, 4794 ± 2865; peak 10-min step cadence, 128 ± 10 steps per minute). Beneficial associations were observed between change in brisk steps per day and change in body mass index, waist circumference, HDL-C, and HbA1c. Similar associations were found between peak 10-min step cadence and HDL-C and waist circumference. Interactions by ethnicity revealed change in brisk steps per day and change in peak 10-min step cadence had a stronger association with HbA1c in White Europeans, whereas associations between change in 10-min peak step cadence with measures of adiposity were stronger in South Asians.
Conclusions: Change in the number of daily steps accumulated at a brisk pace was associated with beneficial change in adiposity, HDL-C, and HbA1c; however, potential benefits may be dependent on ethnicity for outcomes related to HbA1c and adiposity.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1249/MSS.0000000000003180 | DOI Listing |
J Proteome Res
September 2025
Department of Neurology, West China Hospital, Sichuan University, Chengdu 610207, China.
Myasthenia gravis (MG) presents significant health and economic challenges. To identify novel biomarkers, we analyzed proteomic data from 52,704 UK Biobank individuals, focusing on 1463 baseline proteins with follow-up >10 years. Baseline and potential MG cases were 1:5 matched to controls by using propensity score matching.
View Article and Find Full Text PDFNeuropsychiatr Dis Treat
August 2025
Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York, USA.
Brexpiprazole is a second-generation antipsychotic with multiple indications, including the treatment of schizophrenia. As a partial dopamine agonist, brexpiprazole differs from most other antipsychotics, yet uncertainties about its full mechanism of action have led to some ambiguity among prescribers. To address this gap, an international panel of psychiatric experts was organized and convened with funding from Otsuka Pharmaceutical Europe Ltd and H.
View Article and Find Full Text PDFBackground And Aims: The role of anti-Müllerian hormone (AMH), a potential marker of the hypothalamic-pituitary-ovarian axis, is not well established in adolescent females. Typical epidemiologic studies use secondary sexual characteristics or chronological age as predictors for AMH. Skeletal maturity, an indicator of bone development, however, has not been examined in association with AMH in adolescent females.
View Article and Find Full Text PDFFront Sports Act Living
August 2025
Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Introduction: The primary objectives of the present individualized randomized controlled trial were to increase physical activity (PA) and improve physical fitness.
Materials And Methods: 260 military employees around Finland participated. Two-thirds, (158), were randomized in the intervention and one-third, (101), in the control group.
Sleep Adv
July 2025
Lindner Center of HOPE Research Institute, Mason, OH, United States.
Study Objectives: Dim light melatonin onset (DLMO) is the best-established marker of central circadian phase and may contribute to unraveling the role of the circadian system in obesity. This study evaluated DLMO among individuals with obesity using a home-based assessment and explored its clinical correlates and procedural variations.
Method: Fifty-eight women (mean [SD] age 40.